<table
    cellpadding="0"
    cellspacing="0"
    width="100%"
    style="min-width: 100%"
    class="stylingblock-content-wrapper"
>
    <tr>
        <td class="stylingblock-content-wrapper camarker-inner">
            <br />
            <span style="font-size: 14px"
                ><span style="font-family: Arial, Helvetica, sans-serif"
                    >Dear Dr. %%LastName%%,<br />
                    <br />
                    <span style="line-height: normal"
                        >I wanted to reach out and share our research center has three open and
                        enrolling clinical trials for advanced gastric or GEJ cancer patients.&nbsp;
                        Below is a brief synopsis of each study:</span
                    ></span
                ></span
            >
            <ol>
                <li>
                    <span style="font-size: 14px"
                        ><span style="font-family: Arial, Helvetica, sans-serif"
                            ><b>KEYNOTE-811:</b> A phase III trial comparing the safety and efficacy
                            of&nbsp;<span style="line-height: normal"
                                ><span lang="EN" style="color: black"
                                    >pembrolizumab or placebo plus trastuzumab plus chemotherapy in
                                    <b>HER2-positive</b> advanced gastric or gastroesophageal
                                    junction adenocarcinoma </span
                                >with
                                <b><span lang="EN" style="color: black">measurable disease</span></b
                                ><span lang="EN" style="color: black">
                                    as defined by RECIST 1.1.
                                </span></span
                            ></span
                        ></span
                    >&nbsp;(<span style="font-size: 14px"
                        ><span style="font-family: Arial, Helvetica, sans-serif"
                            ><span style="line-height: normal"
                                >Clinicaltrials.gov identifier: NCT03615326)</span
                            ></span
                        ></span
                    >
                </li>
                <li>
                    <span style="font-size: 14px"
                        ><span style="font-family: Arial, Helvetica, sans-serif"
                            ><span style="background: white"
                                ><span style="line-height: normal"
                                    ><span lang="EN" style="color: black"
                                        ><b>SPOTLIGHT:</b>&nbsp; A phase III trial comparing the
                                        efficacy, safety and tolerability of zolbetuximab or placebo
                                        plus mFOLFOX6 chemotherapy as treatment for
                                        <b>Claudin 18.2 positive</b></span
                                    >
                                    <span style="color: black">(</span
                                    ><b
                                        ><span lang="EN" style="color: black"
                                            >CLDN18.2 expression in &ge; 75% of tumor cells as
                                            determined by central IHC testing)</span
                                        ></b
                                    ><span lang="EN" style="color: black"
                                        >, <b>HER2-negative</b>, locally advanced unresectable or
                                        metastatic gastric or gastroesophageal junction
                                        adenocarcinoma.</span
                                    >&nbsp;<span style="color: black">Patients must have a </span
                                    ><span lang="EN" style="color: black"
                                        >predicted life expectancy &ge; 12 weeks. (</span
                                    ></span
                                ></span
                            ></span
                        ></span
                    ><span style="font-size: 14px"
                        ><span style="font-family: Arial, Helvetica, sans-serif"
                            ><span style="background: white"
                                ><span style="line-height: normal"
                                    ><span lang="EN" style="color: black"
                                        >Clinicaltrials.gov identifier: NCT03504397)</span
                                    ></span
                                ></span
                            ></span
                        ></span
                    >
                </li>
                <li>
                    <span style="font-size: 14px"
                        ><span style="font-family: Arial, Helvetica, sans-serif"
                            ><span style="background: white"
                                ><span style="line-height: normal"
                                    ><span lang="EN" style="color: black"
                                        ><b>BGB-A317-305:&nbsp;</b> A phase III trial comparing
                                        tislelizumab or placebo in combination with platinum and
                                        fluoropyrimidine as first-line treatment in adults with
                                        inoperable, locally advanced unresectable or metastatic
                                        gastric or gastroesophageal junction adenocarcinoma</span
                                    >
                                    <span style="color: black">with a</span
                                    ><span lang="EN" style="color: black"
                                        >t least 1 measurable lesion as defined per RECIST. Patients
                                        may have received prior neoadjuvant or adjuvant therapy if
                                        it was completed and have no recurrence or disease
                                        progression for at least 6 months but
                                        <b>cannot have previous systemic therapy</b> for locally
                                        advanced unresectable or metastatic gastric/GEJ cancer.
                                        Patients can be ECOG PS &le; 1 within 7 days prior to
                                        randomization. (</span
                                    ></span
                                ></span
                            ></span
                        ></span
                    ><span style="font-size: 14px"
                        ><span style="font-family: Arial, Helvetica, sans-serif"
                            ><span lang="EN"
                                ><span style="line-height: 107%"
                                    >Clinicaltrials.gov identifier: NCT03777657)</span
                                ></span
                            ></span
                        ></span
                    >
                </li>
            </ol>
            <span style="font-size: 14px"
                ><span style="font-family: Arial, Helvetica, sans-serif"
                    ><span style="background: white"
                        ><span style="line-height: normal"
                            ><span lang="EN" style="color: black"
                                >If you have patients you feel may be appropriate candidates for one
                                of the studies, please don&rsquo;t hesitate to contact me on my cell
                                at 561-305-6059. &nbsp;Additionally, my care team is available when
                                I am with patients at 770-400-6568 or via encrypted email
                                <a name="_Hlk13065253">at </a></span
                            ><a
                                href="mailto:GA-clinicaltrials@ctca-hope.com"
                                style="color: #0563c1; text-decoration: underline"
                                >GA-clinicaltrials@ctca-hope.com</a
                            ><span lang="EN" style="color: black">.</span></span
                        ></span
                    ><br />
                    <br />
                    <span style="background: white"
                        ><span style="line-height: normal"
                            ><span lang="EN" style="color: black">Regards, </span></span
                        ></span
                    ></span
                ></span
            ><br />
            <br />
            &nbsp;
        </td>
    </tr>
</table>
